SLC25A26: A Potential Drug Target and Biomarker for Mitochondrial S-AdrenosylMethionine Transporter

Target Name: SLC25A26

NCBI ID: G115286

SLC25A26

Other Name(s): Mitochondrial S-adenosylmethionine transporter | mitochondrial S-adenosylmethionine transporter | SAMC_HUMAN | Solute carrier family 25 member 26 | S-adenosylmethionine mitochondrial carrier protein (isoform a) | Solute carrier family 25, member 26 | S-adenosylmethionine mitochondrial carrier protein | SAMC | solute carrier family 25 member 26 | solute carrier family 25 (S-adenosylmethionine carrier), member 26 | Solute carrier family 25 (mitochondrial carrier; phosphate carrier), member 26 | solute carrier family 25 (mitochondrial carrier; phosphate carrier), member 26 | Solute carrier family 25 member 26, transcript variant 1 | COXPD28 | SLC25A26 variant 1

SLC25A26: A Potential Drug Target and Biomarker for Mitochondrial S-AdrenosylMethionine Transporter

SLC25A26 is a protein that localizes to the mitochondria, where it functions as the S-adenosylmethionine transporter (SAMT). This transporter is essential for the delivery of S-adenosylmethionine (SAM) to the mitochondria, where it plays a crucial role in the production of energy-producing molecules, such as NAD+ and FADH2. SLC25A26 is also involved in the regulation of cellular processes, including cell death, metabolism, and inflammation.

Several studies have identified SLC25A26 as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative disorders, and metabolic disorders. In this article, we will explore the biology of SLC25A26 and its potential as a drug target.

Biomarker Potential

SLC25A26 has been identified as a potential biomarker for various diseases, including cancer, neurodegenerative disorders, and metabolic disorders. One of the major benefits of using SLC25A26 as a biomarker is its potential to be non-invasive and non-procedural. Unlike many other biomarkers, which require invasive procedures or multiple rounds of testing, SLC25A26 can be measured in a relatively simple and non-destructive manner.

For example, some studies have shown that SLC25A26 levels are significantly elevated in the blood and brain of patients with neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease. Additionally, SLC25A26 has been shown to be elevated in the blood and brain of patients with cancer, which may indicate that it plays a role in the development and progression of these diseases.

Drug Target Potential

SLC25A26 has also been identified as a potential drug target for various diseases, including cancer, neurodegenerative disorders, and metabolic disorders. One of the major advantages of using SLC25A26 as a drug target is its involvement in the production of energy-producing molecules, such as NAD+ and FADH2. By targeting SLC25A26, researchers may be able to boost the production of these molecules and improve energy production in cells.

SLC25A26 has also been shown to play a role in the regulation of cellular processes, including cell death, metabolism, and inflammation. By targeting SLC25A26, researchers may be able to inhibit its activity and improve cellular processes, which could lead to a variety of potential therapeutic benefits.

Conclusion

In conclusion, SLC25A26 is a protein that plays a crucial role in the delivery of S-adenosylmethionine (SAM) to the mitochondria and the regulation of various cellular processes. Several studies have identified SLC25A26 as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative disorders, and metabolic disorders. As research continues to advance, SLC25A26 is likely to play an increasingly important role in the development of new therapeutic approaches for a variety of diseases.

Protein Name: Solute Carrier Family 25 Member 26

Functions: Mitochondrial S-adenosyl-L-methionine/S-adenosyl-L-homocysteine antiporter. Mediates the exchange of cytosolic S-adenosyl-L-methionine, the predominant methyl-group donor for macromolecule methylation processes, for mitochondrial S-adenosylhomocysteine(SAH), a by-product of methylation reactions

The "SLC25A26 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC25A26 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets